Cervical Cancer Clinical Trial
Official title:
Effects of Mindfulness-Based Stress Reduction (MBSR) on Immune Response to HPV
RATIONALE: Mindfulness-based stress reduction (MBSR) may reduce patient stress and improve
quality of life. It is not yet known whether mindfulness-based stress reduction is effective
in improving immune response to human papillomavirus in patients with cervical dysplasia.
PURPOSE: This randomized clinical trial is studying whether mindfulness-based stress
reduction (MBSR) or a general diet and physical activity program has any effects on immune
response to human papillomavirus in patients with cervical dysplasia.
OBJECTIVES:
- To evaluate the effects of a standardized mindfulness-based stress reduction (MBSR)
intervention versus a diet and physical activity program on psychosocial well-being
(e.g., perceived stress and quality of life) at post-intervention and subsequent
follow-up time points.
- To evaluate the effects of an MBSR intervention versus a diet and physical activity
program on specific immune response to HPV (i.e., T-cell proliferative response to
HPV16 and intracellular cytokine expression of HPV-stimulated T-cells) at
post-intervention and follow-up time points.
- To examine the extent to which changes in psychosocial well-being mediate the effects
of the intervention on HPV-specific immune response.
- To explore potential mechanisms of action (e.g., self-regulation, expectancies) that
are proposed to be responsible for producing intervention effects on psychosocial
well-being.
OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo a mindfulness-based stress reduction intervention (including
meditation techniques, body scan, awareness of breathing, mindful yoga, eating
meditation, and walking meditation) for 2 hours, once weekly for 8 weeks.
- Arm II: Patients undergo a diet and physical activity program for 2 hours, once weekly
for 8 weeks.
In both arms, questionnaires measuring psychosocial factors, demographics, and behavioral
risk factors are administered to patients at baseline, within 2 weeks of completing the
8-week programs, and then at 6 and 12 months. Treatment continues in the absence of
developing cervical cancer.
Blood is collected for immunologic assays. HPV status and subtype is evaluated in cervical
specimens using standard and real-time PCR techniques. Quality of Life is evaluated at
baseline, post-intervention, and at 6 and 12 months.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
| Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
| Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
| Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
| Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
| Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
| Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
| Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
| Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
| Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |